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Abstract
Background: The role of hormones in focal nodular hyperplasia (FNH) has been investigated with
conflicting results.
Objective: The aim of this study was to evaluate oestrogen and progesterone receptor immunohisto-
chemical expression in FNH and surrounding normal liver (control material).
Methods: Biopsy materials from FNH and control tissue were investigated using an immunostainer.
Receptor expression was graded as the proportion score (percentage of nuclear staining) and oestro-
gen receptor intensity score.
Results: Study material included tissue from 11 resected FNH lesions and two core biopsies in 13
patients (two male). Twelve samples showed oestrogen receptor expression. The percentage of
nuclear oestrogen receptor staining was <33% in eight FNH biopsies, 34–66% in two FNH biopsies,
and >67% in both core biopsies. The better staining in core biopsies relates to limitations of the stain-
ing technique imposed by the fibrous nature of larger resected FNH. Control samples from surrounding
tissue were available for nine of the resected specimens and all showed oestrogen receptor expres-
sion. Progesterone receptor expression was negligible in FNH and control samples.
Conclusions: By contrast with previous studies, the majority of FNH and surrounding liver in this
cohort demonstrated oestrogen receptor nuclear staining. The implications of this for continued oral
contraceptive use in women of reproductive age with FNH remain uncertain given the lack of consis-
tent reported growth response to oestrogen stimulation or withdrawal.
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Introduction
Focal nodular hyperplasia (FNH) is the most common solid
benign liver tumour and is composed of a proliferation of
hepatocytes around a central stellate scar. Histologically, FNH
resembles focal cirrhosis.1 It is a polyclonal, hyperplastic
response to locally disturbed blood flow and thus differs from
hepatic adenomas, which are monoclonal tumours.2,3 A study
by Paradis et al.2 showed X-chromosome inactivation occurs
randomly in a polyclonal tumour and non-randomly in a
monoclonal tumour. In all of the 15 FNH studied by these
authors, X-chromosome inactivation was random. By contrast,
six of seven hepatic adenomas and two hepatocellular
carcinomas showed non-random patterns of X-chromosome
inactivation consistent with monoclonal tumours.2
The liver is a hormone-sensitive organ and expresses both
oestrogen and androgen receptors. Sex hormones have been
implicated as drivers in tumour formation. Longterm use of
oral contraceptives (OCs) has been shown to induce not only
adenomas, but also FNH.4 Baum et al.5 described the associa-
tion between OC pills (OCPs) and hepatic adenomas in 1973.
Liver tumours were relatively rare until the introduction of
OCs in the 1960s.6 Edmonson and Steiner7 found only two
cases of hepatic adenoma in 48 900 autopsies performed in
Los Angeles General Hospital between 1918 and 1954. The
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incidence of hepatic adenoma decreased after the introduction
of modern lower-dose OCPs.4 The role of hormones in FNH is
supported by its high female predominance, younger age of
onset, and high prevalence amongst individuals using OCPs
(50–75% of patients with FNH use OCPs).4,8 Although several
reports recommend the cessation of OCPs in FNH,8–10 there
are few data to support this recommendation other than the
hypothesis that OCs act to accelerate already established
tumours.3 However, such recommendations are inconsistent
with other reports suggesting that low-dose OCs can be main-
tained with FNH given that size changes during follow-up are
rare and do not relate to OC use and that pregnancy is not
associated with FNH changes.11
Hormone receptor immunohistochemical status has been
assessed in hepatic adenomas and hepatocellular carcinomas,
but less so in FNH. The predominance of FNH in females sug-
gests a hormonal pathophysiological process may play a role in
its pathogenesis; however, this has not been clearly proven.
Porter et al.12 found that nuclear oestrogen receptors were
found in much greater amounts in FNH and adenoma com-
pared with the surrounding liver parenchyma, which suggests
the increased sensitivity of these tumours compared with sur-
rounding normal liver. Kubota et al.13 found that neither
tumour expressed oestrogen or progesterone receptors in a
study of two patients with enlarging FNH and a history of
OCP use. Masood et al.14 found no oestrogen receptors in five
patients with FNH, one of whom was male. However, variable
staining techniques may account for differences in study
results.
The aim of this study was to evaluate oestrogen and proges-
terone receptor expression in resected or biopsied FNH and
surrounding normal liver tissue that was considered to repre-
sent control tissue.
Materials and methods
The study was approved by the institutional ethics committees
at the Royal Adelaide Hospital and Flinders Medical Centre.
Consecutive patients submitted to resection or core biopsy of
FNH from 2001 to 2013 at either of these academic tertiary
centres were asked to give consent and were recruited for the
study.
Resected or biopsied FNH tissue and available surrounding
normal tissue (controls) was stained immunohistochemically
for oestrogen and progesterone hormone receptor status using
the Ventana BenchMark ULTRA immunostainer (Ventana
Medical Systems, Inc., Tucson, AZ, USA) and the confirm
rabbit SP1 clone monoclonal antibody for the oestrogen recep-
tor and the confirm rabbit SP1 clone for the progesterone
receptor. Slides were evaluated by two pathologists working
independently. Receptor expression was graded according to
the proportion score (PS) and intensity score (IS). The PS rep-
resents the percentage of nuclei staining for oestrogen and
progesterone receptors according to the following categories:
0%; <1%; 1–10%; 11–33%; 34–66%, and >67%. The IS repre-
sents receptor staining intensity and is categorized as none,
weak, intermediate or strong.
Results
Of 13 patients (median age: 39 years; range: 26–47 years) with
FNH, 11 underwent resection of the lesion and two submitted
to biopsy (Table 1). Resections were undertaken either for
symptom control or because atypical imaging characteristics
had suggested adenoma. Two patients underwent biopsy of a
liver lesion when imaging features were suspicious but not
equivocal for FNH. The median diameter of the 11 resected
lesions was 18 mm (range: 8–95 mm).
Oestrogen receptor expression in FNH
Twelve of the 13 patients demonstrated labelling with the
oestrogen receptor antibody. The intensity of oestrogen receptor
expression is recorded in Table 1. Both core biopsy specimens
showed the highest IS and nuclear oestrogen receptor staining.
Oestrogen receptor expression in normal surrounding
liver
Surrounding normal liver was available for the assessment of
oestrogen receptor expression in control material in nine
patients. The proportion of nuclear staining was similar to that
in FNH tissue in seven of the nine patients.
Progesterone receptor expression in FNH
Eleven of the 13 FNH patients showed no progesterone recep-
tor expression in FNH specimens.
Progesterone receptor expression in normal
surrounding liver
Only one of the nine available control samples demonstrated
progesterone receptor expression. The FNH tissue from this
patient showed no progesterone receptor expression.
Discussion
In this study, the majority of patients with resected or biopsied
FNH demonstrated oestrogen receptor expression. This was
also present in control liver tissue in all patients in whom con-
trol tissue was available. The proportions of nuclear oestrogen
receptor staining were similar in both FNH and normal liver
tissue. Only two of nine patients had differential oestrogen
receptor expression between the surrounding normal liver and
FNH tissue. Progesterone receptor expression was, however,
negligible.
The samples showing the strongest nuclear staining for oes-
trogen receptors were the core biopsies. In addition, many of
the excision specimens showed more prominent reactivity in
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sections obtained from the periphery of the tissue. Formalin
penetrates cellular tissue slowly at a rate of 1 mm per hour
and therefore core biopsies of 1 mm in diameter will fix
rapidly, whereas larger excision specimens will show a similar
degree of fixation only at the edge. Given the staining patterns
seen in the different specimen types, it seems likely that oestro-
gen receptor staining is influenced by fixation and that the best
results are gained using tissue that fixes rapidly (Figs 1–4).
Human liver hepatocytes contain oestrogen receptors, which
render the liver sensitive to hormonal manipulation. Porter
et al.12 studied oestrogen receptors in neoplastic and normal
surrounding liver in three hepatic adenomas, one FNH and
one normal liver sample. They showed that nuclear oestrogen
receptor expression was much greater in adenoma and FNH
compared with surrounding normal liver. This relative increase
in nuclear oestrogen receptor binding capacity in adenoma and
Table 1 Study population showing age, gender, tumour size and oestrogen receptor (OeR) and progesterone receptor (PR) status
Patient Age, years Gender Tumour size, mm Focal Nodular Hyperplasia (FNH) Surrounding normal Liver tissue
(Controls)
OeR nuclei
staining
(PS)
OeR
intensity
score
PRa nuclei
staining
(PS)
OeR nuclei
staining
(PS)
OeR
intensity
score
PRa nuclei
staining
(PS)
1 35 F 8 1–10% Intermediate 0 1–10% Intermediate 0
2 27b F 12 1–10% Weak 0 1–10% Weak 0
3 40 F 21 1–10% Weak 0 1–10% Weak 0
4 43c F 25 1–10% Intermediate 0 <1% Weak 1–10%a
5 39 F 55 1–10% Intermediate 0 1–10% Weak 0
6 47 M 18 11–33% Intermediate 0 11–33% Intermediate 0
7 45 F 11, 50 11–33% Intermediate 0 11–33% Intermediate 0
8 42 F 95 11–33% Weak <1%a 11–33% Weak 0
9 39 F 16, 17, 18 34–66% Intermediate <1%a N/A N/A N/A
10 34 F 25 34–66% Intermediate 0 N/A N/A N/A
11 38 M Core biopsy >67% Strong 0 N/A N/A N/A
12 30d F Core biopsy >67% Strong 0 N/A N/A N/A
13 26c F 45 0 None 0 1–10% Weak 0
F, female; M, male; N/A, not available; PS, proportion score.
aNo PR intensity score but weak.
bPatient with carcinoid.
cPatients with polycystic ovarian syndrome.
dPatient with Turner syndrome.
Figure 1 Low-power photomicrograph showing strongly positive
oestrogen receptor staining (proportion score: >67%) in a core
biopsy of focal nodular hyperplasia (Original magnification 940)
Figure 2 High-power photomicrograph showing strongly positive
oestrogen receptor staining (proportion score: >67%) in a core
biopsy of focal nodular hyperplasia (Original magnification 9400)
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FNH in comparison with normal tissue suggests that FNH and
adenomas may be more prone to hormonal manipulation than
normal liver tissue. Other studies in seven cases of FNH found
no evidence of hormone receptors using immunohistochemical
techniques.13,14 The differences in results may relate to differ-
ences in staining techniques.
A comprehensive study into the pathogenesis of FNH per-
formed by Wanless describes FNH as an abnormal response to
altered blood flow.15 This can occur from anomalous arteries
or angiogenesis in response to local vascular factors, such as
local venous thrombosis, post-thrombotic arteriovenous shunts
and tumour-related angiogenic factors. This process is then
enhanced by systemic factors such as OC use, female gender
and elevated tumour growth factors.15 The support for the
vascular theory of the pathogenesis of FNH lies in several
observations.3 In a study of 247 patients, of whom 148 had
FNH, a higher incidence of haemangioma was seen in those
with FNH compared with those with non-FNH lesions (20%
versus 9%).16 A further study of 275 members of a family with
hereditary haemorrhagic telangiectasia (HHT) found five mem-
bers with FNH, with a prevalence of HHT in these patients of
2.9%.17 Interestingly, this is consistent with the overall preva-
lence of FNH, which is reported to lie between 0.8% and 3.0%
based on studies of 95 and 2500 autopsies.18,19 Another obser-
vation which led to the suggestion that portal hypertension may
contribute to FNH comes from a study of the explanted livers of
130 patients with cirrhosis, in whom the presence of oesophageal
varices was associated with the occurrence of FNH-like nod-
ules.20 This association would support the role of alterations in
vascularization in the pathogenesis of FNH. Other reports have
suggested that although OCP use may not initiate FNH, it can
stimulate pre-existing FNH by promoting growth in size and
through effects on the local vasculature.9,21 A study that com-
pared 33 users of OCPs with FNH with 15 non-users of OCPs
with FNH found a greater degree of vascular alteration, more
fibrosis and increased tumour size in OCP users.8,22
Focal nodular hyperplasia is a benign condition that can be
accurately diagnosed using techniques such as magnetic reso-
nance imaging (MRI).23 Thus, over the course of more than a
decade, in two major tertiary institutions, tumours from only
13 patients were available for testing. Despite the increasing
accuracy of MRI in determining the diagnosis of FNH and its
benign nature, some patients complain of persistent pain and
symptoms caused by the FNH. The other reason for resection
or biopsy is that atypical or inconclusive imaging findings may
be suspicious for an adenoma or other neoplastic lesion.
Interestingly, both male patients in this study showed oes-
trogen receptor expression in their FNH. Luciani et al.24 stud-
ied clinical and imaging findings in 18 men with FNH and
compared them with those in 216 women with FNH. They
found that men were diagnosed at an older age than women,
that the mean size of FNH was smaller in men than in women
and that surgery was performed far more frequently in men
than in women (72% versus 17%). These differences may relate
to a larger proportion of atypical MRI findings and the greater
risk for hepatocellular carcinoma in men.24 There is conflicting
evidence to support the hormonal basis to the pathophysiology
of FNH, but, interestingly, there is evidence linking an
increased risk for FNH with prolonged use of OCs.25 An epi-
demiologic study of 23 women with FNH and 94 control
subjects found contraceptive use was reported in 83% of those
with FNH and 59% of controls, and identified a significant
trend in increased risk for FNH with increased duration of
OCP use [odds ratios (ORs): 1.62 in those using OCPs for
<3 years and 4.48 in those using OCPs for >3 years in com-
parison with that in women who had never used OCPs].26
Heinemann et al.27 performed two parallel case–control studies
in a total of 51 patients with hepatocellular adenomas and 143
with FNH treated at 15 German liver centres between 1990
and 1997 and a comparison group of 240 population controls.
Figure 3 Low-power photomicrograph with lack of progesterone
receptor staining in a core biopsy of focal nodular hyperplasia
(Original magnification 940)
Figure 4 High-power photomicrograph with lack of progesterone
receptor staining in a core biopsy of focal nodular hyperplasia
(Original magnification 9400)
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They found a significant association between FNH and OCP
use, but not between hepatic adenoma and the use of modern
contraceptives. In subjects with <10 years of OCP use, the ORs
for developing hepatocellular adenoma and FNH were 0.96
[95% confidence interval (CI) 0.25–3.39] and 1.52 (95% CI
0.63–3.62), respectively. In subjects with >10 years of OCP use,
the ORs were 1.78 (95% CI 0.50–6.34) for hepatic adenoma
and 2.45 (95% CI 1.03–5.82) for FNH.27
D’Halluin et al.28 followed 44 women with FNH, with a
median tumour size of 56 mm. The tumour remained stable in
19, decreased in 13 and increased in 12 subjects. However, of
the 21/37 women who stopped using OCPs at diagnosis, the
lesion remained stable in 11, decreased in seven and increased
in three. Although D’Halluin et al.28 concluded that hormonal
status had little to do with the disease, it appeared at first
glance that tumour stability and regression were proportion-
ately greater in women who stopped using OCPs (18/21, 86%)
than in the remaining women (14/23, 61%) (P = 0.09). These
findings suggest that in women found to have FNH while tak-
ing OCPs, the cessation of OCPs may be potentially beneficial,
but evidence of such benefit would require a dedicated and
appropriately powered study.
In the most important study to dispute the role of OCPs in the
development of FNH, Mathieu et al.29 studied 216 women. The
authors found that neither size nor number of lesions at baseline
related to OCP use, although the vast majority of their patients
were OCP users (n = 188, 87%). They followed 136 women for a
mean of 23 months (range: 6 months to 9 years), of whom 37%
were lost from follow-up. Of the 89 women who stopped OCPs,
FNH lesions decreased in two women and increased in one. Of
the 26 who continued on low-dose OCPs, one demonstrated the
disappearance of FNH. The 14 non-OCP users and 7 progesto-
gen-only users had no change in the size of their FNH lesions.
The authors concluded that size changes during follow-up were
not influenced by OCP use. This was further supported by follow-
up in 12 patients in this cohort who became pregnant and sub-
mitted to MRI at 2–14 months (mean: 4.3 months) after delivery,
which demonstrated no change in the FNH.
There are data to support the suggestion that pregnancy
does not increase the risk for significant growth or complica-
tions from FNH30–32 and that pregnancy need not be discour-
aged in these patients. In a study conducted by Rifai et al.30 in
20 patients with FNH monitored during pregnancy, three
experienced tumour growth, seven showed a stable tumour size
and 10 showed some degree of involution. In a study by
Weimann et al.,32 conducted in 10 pregnant women, three of
whom were pregnant twice, only one patient developed right
upper quadrant pain in the course of the pregnancy and none
showed an increase in tumour size. However, occasional case
reports have described an increase in the size of FNH and
heightened symptoms during pregnancy.33,34
Although FNH is traditionally associated with a very low to
no incidence of complications, scattered reports suggest that
complications of FNH such as rupture and bleeding do occur,
although much less frequently than in the context of hepatic
adenoma.35–39 Albeit that the majority of patients with FNH
are asymptomatic and are managed conservatively with obser-
vation, patients who develop abdominal pain, marked tumour
enlargement or have atypical imaging findings may require sur-
gery.40,41 On follow-up, up to 13% of patients who are under
surveillance for FNH go on to develop protracted symptoms.42
Hence, it is imperative that the surgeon who diagnoses the
patient with FNH is able to give sound advice on OCP use.
Several contemporary reports recommend the cessation of
OCPs in patients with FNH.25,41
Conclusions
The present study demonstrates that the majority of FNH
lesions and surrounding liver parenchyma express oestrogen
receptors. This has not been demonstrated in previous studies.
The current findings add additional uncertainty to the ongoing
debate of the role of cessation of OCPs in women with FNH,
thereby supporting the case for further study of this issue.
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